AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6362585 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibronectin-rich plasma cryoprecipitate
Number of subjects: 14
Study 6362585 — intervention group
Group type: COMPARATOR
Intervention: Fibronectin-poor cryoprecipitate extracted plasma (placebo)
Number of subjects: 14
Study 3887350 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd‐YAG laser treatment
Number of subjects: 104
Study 3887350 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 104
Study 29124407 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPP educational system (intervention group)
Number of subjects: 18
Study 29124407 — intervention group
Group type: COMPARATOR
Intervention: Conventional training system (control group)
Number of subjects: 18
Study 27655166 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib-capecitabine
Number of subjects: 0
Study 27655166 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine alone
Number of subjects: 0
Study 24323565 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-treated Parkinson's disease cohort
Number of subjects: 1737
Study 23532991 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured weight loss program (dietary modifications, increased physical activity, behavioral changes)
Number of subjects: 332
Study 19930408 — intervention group
Group type: EXPERIMENTAL
Intervention: Early corticosteroid withdrawal (ECSWD)
Number of subjects: 151
Study 19930408 — intervention group
Group type: COMPARATOR
Intervention: Chronic corticosteroid therapy (CCST)
Number of subjects: 151
Study 18077495 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg nifedipine capsule
Number of subjects: 40
Study 18077495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16368828 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl HCl PATS 40 microg for 24 hours
Number of subjects: 484
Study 16368828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 484
Study 16368828 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl HCl PATS
Number of subjects: 484
Study 12925475 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 40 mg/kg
Number of subjects: 160
Study 12925475 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 15 mg/kg
Number of subjects: 160
Study 12925475 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of acetaminophen and ibuprofen
Number of subjects: 160
Study 12925475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 10717327 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine/cisplatin (GC)
Number of subjects: 135
Study 10717327 — intervention group
Group type: COMPARATOR
Intervention: cisplatin/etoposide (CE)
Number of subjects: 135
Study 8789772 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral salbutamol
Number of subjects: 59
Study 8789772 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol and placebo
Number of subjects: 59
Study 8789772 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 59
Study 1523287 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 0
Study 1523287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6823474 — intervention group
Group type: COMPARATOR
Intervention: Supervised laboratory section (Section 1)
Number of subjects: 57
Study 6823474 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent laboratory sections (Section 2 and Section 3)
Number of subjects: 57
Study 30942842 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted quality improvement intervention (case management, audit and feedback reports, distribution of educational materials)
Number of subjects: 1619
Study 30942842 — intervention group
Group type: COMPARATOR
Intervention: Routine practice (control group)
Number of subjects: 1619
Study 30942842 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted quality improvement intervention
Number of subjects: 1619
Study 26969421 — intervention group
Group type: EXPERIMENTAL
Intervention: NACP-containing composite
Number of subjects: 24
Study 26969421 — intervention group
Group type: COMPARATOR
Intervention: Transbond XT (control)
Number of subjects: 24
Study 26316567 — intervention group
Group type: COMPARATOR
Intervention: Solitaire FR
Number of subjects: 144
Study 26316567 — intervention group
Group type: EXPERIMENTAL
Intervention: Merci retriever
Number of subjects: 144
Study 26316567 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue therapy with intra-arterial rtPA
Number of subjects: 144
Study 26316567 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal ganglionic hemorrhage
Number of subjects: 144
Study 23543092 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation
Number of subjects: 121
Study 23543092 — intervention group
Group type: COMPARATOR
Intervention: Matched control condition
Number of subjects: 121
Study 21305483 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol 1 (10 J, 20 J, 50 J, 100 J, 200 J)
Number of subjects: 50
Study 21305483 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol 2 (20 J, 50 J, 100 J, 200 J)
Number of subjects: 50
Study 21305483 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol 1 and Protocol 2
Number of subjects: 50
Study 21305483 — intervention group
Group type: EXPERIMENTAL
Intervention: AFl patients
Number of subjects: 50
Study 21305483 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial energy
Number of subjects: 50
Study 21305483 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 J
Number of subjects: 50
Study 19857068 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenugreek bread (5% fenugreek, 56 g)
Number of subjects: 8
Study 19857068 — intervention group
Group type: COMPARATOR
Intervention: Whole wheat bread (control)
Number of subjects: 8
Study 16406915 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with doxazosin and finasteride
Number of subjects: 3047
Study 16406915 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin alone
Number of subjects: 3047
Study 16406915 — intervention group
Group type: COMPARATOR
Intervention: Finasteride alone
Number of subjects: 3047
Study 15366728 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic fundoplication by experienced surgeons
Number of subjects: 100
Study 15366728 — intervention group
Group type: COMPARATOR
Intervention: Open fundoplication
Number of subjects: 100
Study 15366728 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic intervention
Number of subjects: 100
Study 11562727 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheme I: chloroquine phosphate (150 mg) at 25mg/kg/day for three days (10mg/kg on day 1, 7.5mg/kg on days 2 and 3) plus primaquine (15 mg) at 0.25mg/kg/day for fourteen days
Number of subjects: 120
Study 11562727 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheme II: chloroquine in a single dose of 10mg/kg plus primaquine at 0.5mg/kg/day for seven days
Number of subjects: 120
Study 11562727 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheme III: chloroquine in a single dose of 10mg/kg plus primaquine at 0.5mg/kg/day for five days
Number of subjects: 120
Study 9535953 — intervention group
Group type: EXPERIMENTAL
Intervention: Catchlike-inducing trains (CITs)
Number of subjects: 12
Study 9535953 — intervention group
Group type: COMPARATOR
Intervention: Constant-frequency trains (CFTs)
Number of subjects: 12
Study 8162980 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy at 2 l.min‐1 at rest
Number of subjects: 34
Study 8162980 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily activities (as reported in questionnaire)
Number of subjects: 34
Study 8162980 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy (prescribed based on blood gas measurements at rest)
Number of subjects: 34
Study 3202450 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled histamine
Number of subjects: 6
Study 3202450 — intervention group
Group type: COMPARATOR
Intervention: Phosphate-buffered saline (PBS)
Number of subjects: 6
Study 4939600 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 4 mg four times daily for four weeks
Number of subjects: 12
Study 4939600 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol 2 mg four times daily for four weeks
Number of subjects: 12
Study 4939600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31219755 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior hypogastric nerve block (SHNB)
Number of subjects: 0
Study 31219755 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 0
Study 27317878 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of tenofovir disoproxil fumarate/lamivudine/efavirenz 300/300/600 mg
Number of subjects: 48
Study 27317878 — intervention group
Group type: COMPARATOR
Intervention: Individual innovator products
Number of subjects: 48
Study 27317878 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 48
Study 25381449 — intervention group
Group type: EXPERIMENTAL
Intervention: OPUS treatment
Number of subjects: 547
Study 25381449 — intervention group
Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 547
Study 23783829 — intervention group
Group type: COMPARATOR
Intervention: Standard physical activity recommendation
Number of subjects: 423
Study 23783829 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐administered implementation intention
Number of subjects: 423
Study 23783829 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone‐assisted implementation intention
Number of subjects: 423
Study 21696265 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP)
Number of subjects: 313
Study 21696265 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pbo)
Number of subjects: 313
Study 20209978 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture + Rehabilitation (Acup + Rehab)
Number of subjects: 50
Study 20209978 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation (Rehab)
Number of subjects: 50
Study 16825290 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramyocardial injections of VEGF‐A(165) plasmid followed by G‐CSF (10 microg/kg/day for 6 days)
Number of subjects: 16
Study 16825290 — intervention group
Group type: COMPARATOR
Intervention: Intramyocardial injections of VEGF‐A(165) plasmid
Number of subjects: 16
Study 16825290 — intervention group
Group type: COMPARATOR
Intervention: Intramyocardial injections of placebo
Number of subjects: 16
Study 15210258 — intervention group
Group type: EXPERIMENTAL
Intervention: IMCI training
Number of subjects: 0
Study 15210258 — intervention group
Group type: EXPERIMENTAL
Intervention: IMCI training in bilingual consultations
Number of subjects: 0
Study 15210258 — intervention group
Group type: EXPERIMENTAL
Intervention: IMCI training in monolingual (Bambara) consultations
Number of subjects: 0
Study 15210258 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug consultations in French and Bambara
Number of subjects: 0
Study 15210258 — intervention group
Group type: EXPERIMENTAL
Intervention: IMCI training overall
Number of subjects: 0
Study 11058663 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast biphasic compression
Number of subjects: 0
Study 11058663 — intervention group
Group type: COMPARATOR
Intervention: Standard monophasic compression
Number of subjects: 0
Study 9286849 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 50 mg
Number of subjects: 1116
Study 9286849 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 100 mg
Number of subjects: 1116
Study 9286849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1116
Study 8269656 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow rate of 250 cc/min
Number of subjects: 10
Study 8269656 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow rate of 350 cc/min
Number of subjects: 10
Study 8269656 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow rate of 450 cc/min
Number of subjects: 10
Study 8269656 — intervention group
Group type: COMPARATOR
Intervention: Comparison between the three different blood flow rates (250, 350, 450 cc/min)
Number of subjects: 10
Study 3318438 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (SAMe)
Number of subjects: 17
Study 3318438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 30445682 — intervention group
Group type: EXPERIMENTAL
Intervention: Synergy 1 (10 g)
Number of subjects: 34
Study 30445682 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 34
Study 27676142 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate continuous exercise
Number of subjects: 10
Study 27676142 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐intensity interval exercise
Number of subjects: 10
Study 25306258 — intervention group
Group type: EXPERIMENTAL
Intervention: MuGard
Number of subjects: 20
Study 25306258 — intervention group
Group type: COMPARATOR
Intervention: Saline-bicarbonate control
Number of subjects: 20
Study 22677192 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril-indapamide
Number of subjects: 11140
Study 22677192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11140
Study 20971245 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW group (target INR range of 1.8 to 2.8 for aortic valve replacement and 2.5 to 3.5 for mitral or double valve replacement)
Number of subjects: 1137
Study 20971245 — intervention group
Group type: EXPERIMENTAL
Intervention: VL1 group (target INR set at 2.0, range 1.6 to 2.1 for aortic valve replacement)
Number of subjects: 1137
Study 20971245 — intervention group
Group type: EXPERIMENTAL
Intervention: VL2 group (target INR set at 2.3, range 2.0 to 2.5 for mitral or double valve replacement)
Number of subjects: 1137
Study 20971245 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW group
Number of subjects: 1137
Study 20971245 — intervention group
Group type: EXPERIMENTAL
Intervention: VL1 group
Number of subjects: 1137
Study 20971245 — intervention group
Group type: EXPERIMENTAL
Intervention: VL2 group
Number of subjects: 1137
Study 20971245 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 1137
Study 19019658 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane F(D) of 6.5% for 15 minutes followed by 5.5% thereafter
Number of subjects: 42
Study 19019658 — intervention group
Group type: EXPERIMENTAL
Intervention: O(2)/N(2)O FGF setting change from 6 to 0.7 L per minute after three minutes
Number of subjects: 42
Study 16898280 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation training (two-phase)
Number of subjects: 50
Study 16898280 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation training (three-phase)
Number of subjects: 50
Study 16898280 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study 12805060 — intervention group
Group type: EXPERIMENTAL
Intervention: AML with 11q23/MLL rearrangement
Number of subjects: 54
Study 12805060 — intervention group
Group type: COMPARATOR
Intervention: De novo AML with MLL rearrangement
Number of subjects: 54
Study 12805060 — intervention group
Group type: COMPARATOR
Intervention: therapy‐related AML (t‐AML)
Number of subjects: 54
Study 12805060 — intervention group
Group type: COMPARATOR
Intervention: t(9;11) MLL rearrangements
Number of subjects: 54
Study 12805060 — intervention group
Group type: COMPARATOR
Intervention: Other MLL rearrangements
Number of subjects: 54
Study 12805060 — intervention group
Group type: COMPARATOR
Intervention: AML M4, M5a, and M5b subtypes
Number of subjects: 54
Study 12805060 — intervention group
Group type: COMPARATOR
Intervention: All other FAB subtypes
Number of subjects: 54
Study 10739409 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/day of haloperidol
Number of subjects: 22
Study 10739409 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/day of haloperidol
Number of subjects: 22
Study 10739409 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mg/day of haloperidol (for non-responders)
Number of subjects: 22
Study 8796820 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fluid bolus with 1 L of normal saline administered over 30 minutes
Number of subjects: 13
Study 8796820 — intervention group
Group type: COMPARATOR
Intervention: No hydration (control group)
Number of subjects: 13
Study 8796820 — intervention group
Group type: COMPARATOR
Intervention: Comparison of hydration vs no hydration
Number of subjects: 13
Study 8198236 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 16
Study 8198236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3127916 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous DDAVP (0.3 micrograms/Kg)
Number of subjects: 14
Study 3127916 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous DDAVP (0.3 micrograms/Kg)
Number of subjects: 14
Study 29764629 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious Game (SG)
Number of subjects: 117
Study 29764629 — intervention group
Group type: COMPARATOR
Intervention: Text-Based Scenario (TBS)
Number of subjects: 117
Study 26739272 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory women's group intervention
Number of subjects: 5355
Study 26739272 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 5355
Study 25763525 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention (FNI)
Number of subjects: 76
Study 25763525 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 76
Study 24506387 — intervention group
Group type: EXPERIMENTAL
Intervention: 3g of a 1:1 mix of c9‐t11 and t10‐c12 in skimmed milk
Number of subjects: 38
Study 24506387 — intervention group
Group type: COMPARATOR
Intervention: 3g olive oil (placebo)
Number of subjects: 38
Study 21177801 — intervention group
Group type: COMPARATOR
Intervention: Dietary intervention with a focus on habitual dietary patterns
Number of subjects: 160
Study 18509204 — intervention group
Group type: EXPERIMENTAL
Intervention: HRQoL intervention group
Number of subjects: 91
Study 18509204 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 91
Study 16547088 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 2 mg ml(-1) (0.2%)
Number of subjects: 60
Study 16547088 — intervention group
Group type: COMPARATOR
Intervention: Prilocaine 5 mg ml(-1) (0.5%)
Number of subjects: 60
Study 14585084 — intervention group
Group type: EXPERIMENTAL
Intervention: Human GH 0.1 IU/kg per day for 4 days
Number of subjects: 23
Study 10924807 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose fentanyl (112 microg bolus followed by 0.04 microg/kg per min infusion)
Number of subjects: 20
Study 10924807 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose fentanyl (56 microg bolus followed by 0.02 microg/kg per min infusion)
Number of subjects: 20
Study 10924807 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (50 cc bolus followed by 45 cc/h infusion)
Number of subjects: 20
Study 10924807 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (both doses)
Number of subjects: 20
Study 7796344 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 IU of salmon calcitonin intranasally daily for 1 year
Number of subjects: 150
Study 7796344 — intervention group
Group type: COMPARATOR
Intervention: Placebo intranasal spray daily for 1 year
Number of subjects: 150
Study 2121325 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (1.5 micrograms/kg/min) alone
Number of subjects: 19
Study 2121325 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (1.5 micrograms/kg/min) with oral captopril (63 +/- 8 mg/day)
Number of subjects: 19
Study 619947 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (300 μg)
Number of subjects: 5
Study 619947 — intervention group
Group type: EXPERIMENTAL
Intervention: UK-14,304 (750 μg)
Number of subjects: 5
Study 619947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 31370191 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 87
Study 31370191 — intervention group
Group type: COMPARATOR
Intervention: Self-help brochure (control)
Number of subjects: 87
Study 28187918 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen+diazepam
Number of subjects: 114
Study 28187918 — intervention group
Group type: COMPARATOR
Intervention: naproxen+placebo
Number of subjects: 114
Study 26113445 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep
Number of subjects: 0
Study 26113445 — intervention group
Group type: COMPARATOR
Intervention: Wake
Number of subjects: 0
Study 22997048 — intervention group
Group type: EXPERIMENTAL
Intervention: Generous grading by professors
Number of subjects: 3
Study 22997048 — intervention group
Group type: COMPARATOR
Intervention: Frugal grading by professors
Number of subjects: 3
Study 22997048 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor feedback
Number of subjects: 3
Study 22997048 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive grade/feedback condition
Number of subjects: 3
Study 22023735 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate and high calorie oral nutritional supplement
Number of subjects: 200
Study 22023735 — intervention group
Group type: COMPARATOR
Intervention: Placebo medication and low calorie oral nutritional supplementation
Number of subjects: 200
Study 19628319 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose B vitamin capsule (40 mg of folic acid, 100 mg of vitamin B6, and 2 mg of vitamin B12)
Number of subjects: 659
Study 19628319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 659
Study 16733228 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (1 mg/day)
Number of subjects: 86
Study 16733228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 14998605 — intervention group
Group type: EXPERIMENTAL
Intervention: Declined entry into randomised clinical trials of adjuvant cancer therapy
Number of subjects: 22
Study 11150899 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg diazepam
Number of subjects: 12
Study 11150899 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg diazepam
Number of subjects: 12
Study 11150899 — intervention group
Group type: COMPARATOR
Intervention: Inert placebo
Number of subjects: 12
Study 9385303 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized display of charges for clinical laboratory tests
Number of subjects: 12271